Premium
Polo‐like kinase (Plk) 1 as a target for prostate cancer management
Author(s) -
ReaganShaw Shan,
Ahmad Nihal
Publication year - 2005
Publication title -
iubmb life
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.132
H-Index - 113
eISSN - 1521-6551
pISSN - 1521-6543
DOI - 10.1080/15216540500305910
Subject(s) - polo like kinase , plk1 , prostate cancer , mitosis , kinase , cytokinesis , cancer research , cancer , medicine , disease , oncology , biology , cell cycle , microbiology and biotechnology , cell division , cell , genetics
Prostate cancer (PCa) is the most commonly occurring cancer in American men, next to skin cancer. Existing treatment options and surgical intervention are unable to effectively manage this cancer. Therefore, continuing efforts are ongoing to establish novel mechanism‐based targets and strategies for its management. The serine/threonine kinases Polo‐like kinase (Plk) 1 plays a key role in mitotic entry of proliferating cells and regulates many aspects of mitosis which are necessary for successful cytokinesis. Plk1 is over‐expressed in many tumor types with aberrant elevation frequently constituting a prognostic indicator of poor disease outcome. This review discusses the studies which indicate that Plk1 could be an excellent target for the treatment as well as chemoprevention of prostate cancer.IUBMB Life, 57: 677‐682, 2005